ReviewACS pharmacology & translational science2025
Lipids: Driving Forces in the Underlying Biology of Carcinogenesis.
Review in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Resveratrol Modulates Phosphatidylcholine Metabolism-Related Enzymes and Enhances Chemosensitivity in Colorectal Cancer Models.International journal of molecular sciences · 2026Article
- Review
- Article
- Evaluating the potential causal relationship between carnitine-related metabolites and breast cancer: a Mendelian randomization and transcriptomic analysis.Archives of medical science : AMS · 2026Article
- Multi-omics unravel heterogeneity of glucose metabolism reprogramming in gastric cancer.Clinical and experimental medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipids, mainly composed of cholesterol, phospholipids, sphingolipids, triacylglycerides, and fatty acids, have vital functions within cells. Some lipids function as signaling molecules or secondary messengers and are cellular membranes' energy sources and structural elements. More research is being conducted on metabolic reprogramming as a hallmark of cancer. However, compared with the metabolism of glucose or glutamine, lipid metabolism in cancer has received less attention. There is increasing evidence that certain parts of the lipid metabolism are altered in cancer cells. The alterations could influence the quantity of lipids involved in signaling functions, affect the synthesis and breakdown of lipids necessary for maintaining energy homeostasis, and modify the availability of structural lipids critical for membrane formation. The term "lipid metabolic reprogramming" refers to modifications in the lipid metabolism that can impact cellular processes such as cell division, growth, proliferation, and the cell cycle, ultimately resulting in cancer. Furthermore, interactions between cancer cells and nearby immune cells via an altered lipid metabolism promote the development and spread of tumors. The most recent studies on the involvement of lipid metabolism in different cancers and associated hallmarks and lipids in various aspects of cancer therapeutics, which affect multiple facets of tumorigenesis, are described in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.